Although ADPN has not yet shown significant potential as a diagnostic biomarker for eating disorders (i.e., not stratifying patients according to diagnostic severity), ADPN may serve as a prognostic biomarker, providing clinical guidance for these patients, potentially informing on the metabolic risk of single patients. Here, ADIPOQ is linked to eating disorder.